Skip to main content

Table 3 Multivariate analysis of factors associated with DFS and OS

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Characteristics DFS OS
HR (95% CI) P value HR (95% CI) P value
Menstrual status (Post - vs. Pre/Peri-) / / 2.33 (1.69–3.22) <  0.001
Neo-adjuvant therapy (Yes vs. No) 2.51 (1.91–3.30) <  0.001 2.39 (1.61–3.56) <  0.001
Breast surgery (BCS vs. Mastectomy) 1.00 (0.77–1.30) 0.992 0.73 (0.47–1.12) 0.149
Tumor size (>  2.0 cm vs. ≤ 2.0 cm) 1.54 (1.26–1.88) <  0.001 1.81 (1.32–2.48) <  0.001
ALN status (Positive vs. Negative) 1.58 (1.29–1.93) <  0.001 2.15 (1.57–2.93) <  0.001
Histological grade   <  0.001   <  0.001
III vs. I/II 1.44 (1.15–1.81)   1.69 (1.19–2.40)  
NA vs. I/II 1.58 (1.21–2.06)   2.02 (1.36–3.01)  
LVI (Yes vs. No) 1.26 (0.90–1.75) 0.176 1.55 (0.94–2.54) 0.084
ER   0.074   <  0.001
10–49% vs. 1–9% 1.18 (0.72–1.94)   0.95 (0.52–1.73)  
≥ 50% vs. 1–9% 0.89 (0.55–1.45)   0.44 (0.24–0.78)  
PR (≥ 20% vs. <  20%) 0.82 (0.67–1.00) 0.050 0.77 (0.55–1.07) 0.118
Ki-67 (≥ 14% vs. <  14%) 1.49 (1.21–1.85) <  0.001 1.43 (1.02–2.00) 0.037
Radiotherapy (Yes vs. No) 0.97 (0.78–1.21) 0.790 1.09 (0.74–1.59) 0.675
Chemotherapy (Yes vs. No) 1.15 (0.91–1.46) 0.236 0.94 (0.66–1.35) 0.744
Endocrine therapy (Yes vs. No) 0.56 (0.41–0.76) <  0.001 0.46 (0.30–0.71) <  0.001
Group (HER2-pos-T vs. HER2-neg) 0.52 (0.37–0.73) <  0.001 0.38 (0.22–0.67) 0.037
  1. HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; ALN, axillary lymph node; LVI, lymph-vascular invasion; ER, estrogen receptor; PR, progesterone receptor; y/o, years old